•

**EXHIBIT 18** 

### **Inhalation Drug Products in** LDPE Containers: A Quality (CMC) Perspective

### Vibhakar Shah, Ph.D.

**Pulmonary and Allergy Drug Products Division of New Drug Chemistry II** Office of New Drug Chemistry, OPS, CDER, FDA



Drug Safety and Risk Management Advisory Committee May 05, 2004

### **Outline**

- > Inhalation Drug Products
- > Container-Closure System Overview
- > FDA Analytical Survey and Other **Data**
- > Quality Concerns
- > Potential Approaches
- > Recommendations for Packaging
- > Summary



## **Inhalation Drug Products**

- >Inhalation Solution
- > Inhalation Suspension
- ➤ Inhalation Spray
  - ◆ Solution
  - ◆ Suspension
- ➤ Inhalation Aerosol (Metered Dose Inhaler)
  - Solution
  - ◆ Suspension
- ➤ Inhalation Powder (Drug Powder Inhaler)



DSARMAC, May 05, 2004

## **Drug Product Examples**

- ➤ Albuterol SO₄ Inhalation Solution
- > Levalbuterol HCl Inhalation Solution
- > Ipratropium Br Inhalation Solution
- ➤ Albuterol SO<sub>4</sub> and Ipratropium Br Inhalation Solution
- ➤ Metaproterenol SO<sub>4</sub> Inhalation Solution
- > Cromolyn Na Inhalation Solution
- > Budesonide Inhalation Suspension
- > Tobramycin Inhalation Solution



### **Current Container-Closure System**

#### **Inhalation Solution and Suspensions:**

- > Unit-Dose containers/Vials (UDV)
  - ◆ LDPE vials
  - ◆ Blow-Fill-Seal/Form-Fill-Seal Process
- > Vial label
  - ◆ Emboss, Deboss
  - ◆ Self-adhesive Paper label
- > Foil overwrap pouch (1, 4, 5, 12 vials/pouch)
  - ◆ Pre-printed
  - ◆ Self-adhesive Paper label



DSaRMAC, May 05, 2004

# **Container-Closure Components**

**LDPE** vial



### **LDPE Characteristics**

>Low density polyethylene (LDPE) is a polyethylene homo-polymer resin:

$$-[-CH_2-CH_2-]_n-$$

- > Resin Components:
  - Reactant monomer, Chain transfer agent, Chain initiator, Antioxidant, Stabilizers, Slip Additive, Superfloss Antiblock additive
- > Different grades for different applications
- ➤ Many sources: Manufacturers, suppliers



DSARMAC, May 05, 2004

### **LDPE Vial Properties**

- > Flexible and malleable
- > Stress crack, impact and tear resistant
- > Considered chemically inert at room temperature
- > May be usable up to 80°C for extended periods
- > Sterilizable
- > Amenable to high speed production lines
- > Aesthetically, clear to translucent to opaque
- > Permeable to volatile chemicals and gases



# **Container-Closure Components**

# Paper label



DSaRMAC, May 05, 2004

### **Typical Paper label Components**

- > Calcium Carbonate
- > Kaolin Clay
- > Ethylated Corn Starch
- > Cationic Potato Starch
- > Sodium Bicarbonate
- > AKD
- > Colloidal Silica
- > Liquid Alum
- ➤ Latex Calcium
- > Stearate

- > Viscosity Modifier
- > Polyvinyl Alcohol
- > Ammonium Zirconium Carbonate
- > Carboxymethylcellulose
- > Dispersant
- > Microbiocide
- > Fluorescent Dye
- > Pigment Dye



DSaRMAC, May 05, 2004

### **Typical Adhesive Components**

- >Aromatic C5 hydrocarbon resin
- > Polymeric hindered phenol (Anti-oxidant)
- > Diasteary I pentaerythrotol diphosphate (Anti-oxidant)
- > Styrene-isoprene-styrene block polymer,
- ➤ Naphthenic Oil
- ➤ Liquid C5 hydrocarbon resin



DSaRMAC, May 05, 2004

11

### **Typical Over-lacquer Components**

- > Joncryl 60, 89, 624
- > Wax dispersions (e.g., Liquitron 345)
- > Defomers (e.g., Tego Foamex 1488)
- > Non silicone Defomers (e.g., Nopco NDW)
- > Grease resistant coating Agents (e.g., Scotchban FC-807)
- > PTFE Dispersions (e.g., Fluotron 300)

- ➤ Slip Additives (e.g., Dow 51 Additive
- > Lucidene 614
- ➤ Morcryl 360
- > Surfactants (e.g., Aerosol OT-75)
- Syloid silicas
- > Methyl-n-2-pyrrolidone
- > Aqua Ammonia
- Normal propanol
- > Water



DSaRMAC, May 05, 2004

# **Typical Ink Components**

- ➤ Acrylic resin
- > Styrene acrylic polymers
- > Surfactant
- > Cellulosic defoamer
- > Maleic resin chip
- ➤ Pigment Dyes:
  - ◆ Carbazole violet 23
  - ◆ Phthalocyanine blue
  - ◆ Phthalocyanine green 7

- ➤ Pigment Dyes:
  - ◆ Red 238
  - ◆ Violet 23
  - ◆ Black 7
  - ♦ Yellow 74
  - ◆ Green 7
  - ◆ Blue 15
  - ◆ Red 57
  - ◆ Violet 3



DSaRMAC, May 05, 2004


# **Container-Closure Components**

Foil-laminate



### **Typical Foil-laminate Components**

A B C D E F G H



H G F ED CB A

A = Exterior layer Polyester/PP/PE (0.00048 inch)

B = Inks

C = Adhesive1

Aluminum

Foil (0.00035 inch) E = Adhesive2

F = Nylon/Polyester/ PP/PE(0.001 inch)

G = Adhesive3

H = Interior layer Polyester/PP/PE (0.003 inch)



DSaRMAC, May 05, 2004

### **LDPE Vial Permeability: Implications**

- > Contamination of drug product with ingress of volatile chemicals from the environment that may be irritants or toxic to the respiratory tract, and may sensitize individuals.
- > Degradation of the drug products in LDPE vials by reactive gases and light.
- > Water evaporation through LDPE vials, altering the concentration of drug product in LDPE vials.
- > Potential acceleration of drug product degradation (impurities) due to change in drug concentration.



DSaRMAC, May 05, 2004

# **FDA Analytical Survey** and **Other Supportive Data**



DSaRMAC, May 05, 2004

### **FDA Analytical Survey**

- > Initiated by OGD & DPADP/OND in coordination with OC/ORA Field Offices and Pacific Regional Laboratory.
- > 7 ANDAs and 1 NDA for Inhalation solutions covering five different drug substances.
  - ◆ 38 samples representing 37 Lots of various drug products in LDPE vials without a protective overwrap foil-pouch.
  - Samples screened for potential volatile chemicals such as vanillin, 2-phenoxyethanol, and 1-phenoxy-2propanol by GC-MS (sensitivity ~ 0.5 ppm) and HPLC methods.



#### **FDA Analytical Survey: Results**

- > 29 out of 38 samples tested positive for chemical contamination originating from packaging.
- > Detected 5 known chemical contaminants originating from packaging.
  - ◆ Benzophenone (2 lots)
  - ◆ Polyethylene glycols (n = 4 -8), (3 lots)
  - ◆ 2-(2-Butoxyethoxy)ethanol (DEGBE), (24 lots)
  - ◆ 2-(2-Ethoxyethoxy)ethanol acetate (DEGEEA), (3 lots)
  - ◆ 2-Hydroxy-2-methylpropiophenone (2-HMPP), (5 lots)



DSaRMAC, May 05, 2004

### **FDA Analytical Survey: Conclusion**

- > Potential for these chemicals to cause bronchospasm at levels detected is unknown, especially, in patients with respiratory diseases.
- Concentration of these chemicals might be greater at the end of expiry than what was detected.
- ➤ Ingress/Leaching of chemical contaminants into drug product formulations from packaging components demonstrates that **permeation** through LDPE is a real phenomenon.
- > Additional chemicals may be present, but may not get detected by the analytical procedures used.
- > Future changes in the materials used in labeling and packaging may result in contamination with different chemicals.



FD/ DSaRMAC, May 05, 2004

### **Typical Sources of Product** Contamination

- > Formulation components (Degradation)
  - Drug substance, excipients, formulation vehicle
- Resin components (Leaching)
  - Monomer, dimer, antioxidants, plasticizers, catalysts etc.,
- Paper label components (Leaching)
  - Paper, adhesive, varnish/over lacquer, inks, residual volatile solvents
- > Foil overwrap components (Leaching)
  - · Adhesive, residual volatile solvents
- > Cartons (Leaching)
  - Adhesive, residual volatile solvents
- Environment (Leaching)
  - Reactive gases, volatile pollutants



DSaRMAC, May 05, 2004

### **Extractable/Leachable: Examples**

- > Resin components
  - ◆ Irganox 129, 2, 2, 6-trimethyloctane
- > Paper label components
  - ◆ Benzoic acid, ethyl phthalate, benzophenone, Danocur 1173, cyclic phthalates
- > Foil overwrap components (Leaching)
  - ◆ Methacrylic acid, 2-phenoxyethanol
  - ◆ Acetone, 2-butanone, ethylacetate, propylacetate, heptane, toluene
- > Cartons (Leaching)
  - ◆ Methacrylic acid, 1-phenoxy-2-propanol



### **Quality Concerns**

- > Proprietary components and composition of packaging materials.
- > Change in the components and composition of these materials without the knowledge of applicant and the Agency.
- > No one analytical procedure to detect known/unknown chemical contaminants.
- > Incomplete toxicological data for many of the identified chemical contaminants.
- > Variable environmental conditions may introduce new contaminants.



DSaRMAC, May 05, 2004

23

# **Potential Approaches**



### **Agency's Quality Control Approach**

- > Characterize/Identify all possible extractables and establish a profile for each packaging component (e.g., resin, vial, paper label, foil-laminate overwrap).
- > Establish a correlation between *extractable* and its leachable potential.
- > Set meaningful acceptance criterion for a given extractable in corresponding incoming packaging components, based on its qualification level and actual observed data.
- > Set meaningful acceptance criterion for a given leachable based on actual observed data in the drug product.



DSaRMAC, May 05, 2004

25

### **Extractable & Extractable Profile**

- > Extractable is a chemical compound (volatile, non-volatile) that gets extracted from à packaging component in a suitable solvent by utilizing optimum extraction conditions (time and temperature).
- Extractable profile for a given packaging component, typically can be a chromatogram (GC, HPLC, GC-MS, LC-MS) representing all possible extractables.
- Extractable profile is established for all packaging components (resin, vial, foil-laminate) for their consistent quality assurance.





### Leachable

- > Leachable is any chemical compound (volatile, non-volatile) that leaches into the drug product formulation either from a packaging component or local environment on storage (time and temperature) through expiry of the drug product. An extractable can be a leachable.
- > To ensure batch-to-batch consistency of the drug product, appropriate specification (test method, acceptance criteria) for a leachable is established based on its qualification (toxicity) and observed levels in the drug product on storage.



DSaRMAC, May 05, 2004

### Recommendations

#### Recommendations

- > Adequate knowledge of composition and physico-chemical properties of packaging components for appropriate selection.
  - Resin components, foil-laminate, paper label, inks (aqueous vs. non-aqueous base), etc.
- > Discourage paper label directly on the LDPE vial.
- > Encourage alternative approaches, including embossing/debossing in lieu of the paper label on the LDPE Vial.
  - Extended bottom flanges to UDV to carry essential vial labeling information and product identity.



DSaRMAC, May 05, 2004



#### Recommendations

- > Use of protective overwrap foil-pouch for the LDPE unit-dose vial (UDV)
  - ◆ Can minimize ingress and leaching of chemical contaminants from the local environment.
- > Self-adhesive paper label on a foil-pouch or preprinted foil-pouch and different color schemes to differentiate multiple strengths of the drug product.
  - Prevent ingress/leaching of chemical contaminants from paper labels and also improve the legibility issues.





### Recommendations

- Limit the number of unit-dose-vials per pouch, ideally to one LDPE vial per foilpouch.
  - ◆ Minimize the risk of medication error by patients and health care professionals
  - Prevent unnecessary exposure to local environment (When compared to packaging of multi UDVs/Foil-pouch)



DSaRMAC, May 05, 2004



### **Summary**

- > Volatile chemicals present in the packaging components and local environment have great potential to permeate through LDPE vials into drug product formulation on storage (time and temperature).
- > Agency's Analytical Survey and other supportive data have confirmed ingress/leaching of such volatile chemicals into the drug product formulations.



DSaRMAC, May 05, 2004

### **Summary**

- > Ingress/leaching of such chemicals into drug product formulation poses a safety concern for patients with respiratory illness (Asthma, COPD).
- > Embossing/debossing of LDPE vial in lieu of paper label is recognized to have legibility issue.
- > Paper labels, although perceived to address legibility issue, overall may not be the optimum solution because of the safety concerns associated with potential leaching/ingress of paper label components in the drug product through LDPE vial.



DSaRMAC, May 05, 2004

### **Summary**

- > Agency's current recommendations as stated in the draft guidance may serve as a first step in right direction to address the issues that are being discussed today.
- > Agency is seeking other <u>viable</u> approaches to address these issues to promote safe product use without compromising the integrity of the drug product.



# **Inhalation Drug Products in LDPE Containers: A Quality Perspective**


# Thanks.



**Blow-Fill-Seal (BFS)** a.k.a Form-Fill-Seal (FFS) **Process** 

FDA DSaRMAC, May 05, 2004

#### **Blow-Fill-Seal / Form-Fill-Seal Processes**




#### **Extrusion**

- > Thermoplastic resin beads are pneumatically fed into the B/F/S machine. The beads enter an extruder where they are melted by heat generated by electric band heaters and physical compression.
- > The molten thermoplastic is then continuously extruded through an orifice in a tubular shape [parison,
- > The machine simultaneously extrudes six parisons per machine cycle and forms/fills four vials per parison. Filtered ballooning air continuously passes through the formed parison to maintain its shape.




DSaRMAC, May 05, 2004

#### **Blow-Fill-Seal / Form-Fill-Seal Processes**




#### **Blow & Fill**




- > When the tube (parison) reaches the proper length, the main mold (B) closes and the parison is cut off at (C).
- > The bottom of the parison is pinched closed and the top is held open by a set of holding jaws (D).
- > Vacuum ports in the mold cavity walls activate to form the container. The mold then moves to a position under the filling nozzle.
- > The filling nozzle (E) lowers Into the parison unit it forms a seal with the neck of the mold.
- > A metered amount of product is then transferred Into the container.

DSaRMAC, May 05, 2004

#### **Blow-Fill-Seal / Form-Fill-Seal Processes**



#### Seal



- > When the container is filled, the filling nozzle retracts to its original position.
- > At this point in the cycle, the length of parison between the top of the mold and the holding jaws is still semimolten.
- > A sealing mold (F) doses to form the top and hermetically seal the container.
- > Once the container is sealed, the sealing mold, main mold, and holding jaws open. A trim die removes residual plastic (G) and a formed, filled, and sealed container is conveyed out of the machine.



DSaRMAC, May 05, 2004

39

### **Drug Product Examples**

- ➤ Albuterol SO<sub>4</sub> Inhalation Solution (AccuNeb®, Proventil®, Ventolin®)
- Levalbuterol HCl Inhalation Solution (Xopenex®)
- > Ipratropium Br Inhalation Solution (Atrovent®)
- ➤ Albuterol SO<sub>4</sub>/Ipratropium Br Inhalation Solution (DuoNeb®)
- ➤ Metaproterenol SO<sub>4</sub> Inhalation Solution (Alupent®)
- Cromolyn Na Inhalation Solution (Intal®)
- > Budesonide Inhalation Suspension (Pulmicort®)
- > Tobramycin Inhalation Solution (Tobi®)



DSARMAC, May 05, 2004